Systematic evaluation of dose, route of administration, product formulation, and chemical composition on the pharmacokinetics and pharmacodynamics associated with acute cannabis/cannabinoid exposure.

Characterization of the interactive effects between various cannabis constituents (e.g., THC, CBD, and terpenes/minor cannabinoids).

Research to inform workplace and roadside drug testing policies.

Retail cannabis product testing and surveillance.

Assessing performance/impairment (e.g. cognitive, behavioral, simulated driving) after acute cannabis/cannabinoid exposure, both alone and in combination with other impairing substances (e.g., alcohol).